SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on May 28, 2024. The registrant is incorporated in Delaware and its common stock trades on The NASDAQ Capital Market under the symbol BSGM. The filing addresses a critical regulatory event regarding the company's continued listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt. The only financial metric disclosed is a regulatory requirement: the company must demonstrate compliance with the $2.5 million stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1).
Material Changes and Events
- Nasdaq Listing Decision: On May 28, 2024, the Nasdaq Hearings Panel granted the Company's request for continued listing on The NASDAQ Capital Market.
- Compliance Condition: Continued listing is conditional upon the Company evidencing compliance with the $2.5 million stockholders' equity requirement by June 6, 2024.
- Management Action: The Company states it is diligently working to meet the terms of the Panel's decision.
Outlook, Risks, and Contingencies
The primary risk identified is the potential loss of listing status if the Company fails to meet the stockholders' equity requirement by the June 6, 2024 deadline. Management has not provided specific financial guidance or detailed operational outlook beyond the commitment to provide material updates when available.
Investor Verification Checklist
- Verify the Company's current stockholders' equity balance to confirm it meets or exceeds the $2.5 million threshold.
- Monitor for subsequent filings confirming compliance with the June 6, 2024 deadline.
- Review the Company's most recent 10-Q or 10-K for detailed financial statements, as this 8-K does not contain comprehensive financial data.